Vertex Anticipates Completing Enrollment of Phase 3 Trials Testing Triple Combo Therapies
Vertex Pharmaceuticals plans to conclude the enrollment of patients in its Phase 3 programs involving its triple combo therapies to treat...
Vertex, NHS England no closer to Orkambi settlement
Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement...
Nanoparticles Therapy May Be ‘One-Size-Fits-All’ Approach for CF, Study Suggests
A potential therapy delivered through nanoparticles enables production of the normal, healthy form of the key CFTR protein in cystic...
Carlow Cystic Fibrosis sufferer welcoming news that Orkambi will be available for children
A local Cystic Fibrosis sufferer says news that the drug Orkambi will now be available to children is fantastic. The Department of Health...
Orkambi’s Components Trigger Liver Enzyme That Decreases Its Ability to Fight CF, Study Finds
The two components of Orkambi act separately to trigger a liver enzyme that decreases the therapy’s ability to fight cystic fibrosis, a...
GeneFo Releases Updated 2018 Guide to Help Cystic Fibrosis Patients Navigate Treatment Options
GeneFo has put together an updated 2018 guide on treatment options for people with cystic fibrosis (CF) after recent developments again...
Cystic fibrosis drug Orkambi 'approved for use among 6-11 year olds'
The pharmaceutical firm making cystic fibrosis drug Orkambi says it has received EU approval to treat children. Manufacturer Vertex says...
Proteostasis’ CFTR Modulators Show Potential in Improving Effectiveness of Orkambi
Clinical trials on all three Proteostasis Therapeutics’ investigational cystic fibrosis modulators — PTI-428, PTI-801, and PTI-808 — have...
Spyryx Presents Data Ably Supporting SPX-101 as Potential Treatment for All CF Patients
Spyryx Biosciences recently presented preclinical data supporting the clinical benefits of its cystic fibrosis (CF) treatment candidate...
Europe’s CHMP Gives Its Blessing to Vertex’s Orkambi as CF Therapy for Younger Children
The European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Orkambi...
